What is the clinical evidence from this study?

Study design: Other. Population: Doxorubicin-induced cardiotoxicity (n=26). Intervention: 17β-estradiol vs. Doxorubicin + vehicle. Primary outcome: Cardiac ejection fraction and fractional shortening (p=<0.05).

March 16, 2017Molecular Medicine ReportsOpen Access

17β-estradiol protects against doxorubicin-induced cardiotoxicity in male Sprague-Dawley rats by regulating NADPH oxidase and apoptosis genes

Q: What are the key findings of this study?

17β-estradiol treatment significantly attenuated doxorubicin-induced decreases in cardiac ejection fraction and fractional shortening in male rats.

View Full Paper

Ask AI

Bookmark

Key result

17β-estradiol treatment significantly attenuated doxorubicin-induced decreases in cardiac ejection fraction and fractional shortening in male rats.

Why the study?

Does 17β-estradiol prevent doxorubicin-induced cardiotoxicity in male Sprague-Dawley rats?

Population

26 male Sprague-Dawley rats, age 14 weeks, average body weight 402±17 g

Comparison

17β-estradiol 2 mg/kg body weight/day… vs Doxorubicin + vehicle treatment, and…

Design

Preclinical

Follow-up

3 weeks following the first doxorubicin injection

Authors

XZXiaojuan ZhangWuhan Polytechnic University XCXiaoqing CaoNorth China University of Water Resources and Electric Power CZChunsheng ZhangChina National Offshore Oil Corporation (China)

Discussion

Member takes

Implication

Suggests a potential cardioprotective pathway against anthracycline toxicity in males; leaves open whether these.

Structured PICO

Does 17β-estradiol prevent doxorubicin-induced cardiotoxicity in male Sprague-Dawley rats?

Population

26 male Sprague-Dawley rats, aged 14 weeks, were evaluated for the protective effects of 17β-estradiol against doxorubicin-induced cardiotoxicity over a 3-week period.

Intervention

17β-estradiol (E2) 2 mg/kg body weight/day administered subcutaneously, starting 3 days prior to doxorubicin treatment until sacrifice (3 weeks after first doxorubicin injection)

Comparator

Doxorubicin + vehicle treatment, and saline-treated controls

Outcome

Cardiac systolic function (ejection fraction and fractional shortening) and serum biomarkers for heart injury (ALT, AST, LDH, CK) at 3 weekssurrogate

Main Result

p-value: p=<0.05

17β-estradiol protects against doxorubicin-induced cardiotoxicity in male rats by regulating NADPH oxidase and apoptosis genes, highlighting a potential therapeutic target for male patients receiving anthracyclines.

Limitations

Apoptosis was not directly determined in this study
More studies are needed to determine the dose-response and estrogen levels in male animals under physiological and pathological conditions
Dose of E2 used was based on previous reports; more studies are needed to determine the dose-response
Estrogen levels in male animals under physiological and pathological conditions need further investigation

Cite This Study

Zhang et al. (2017) studied Doxorubicin-induced cardiotoxicity (n=26). 17β-estradiol vs. Doxorubicin + vehicle was evaluated on Cardiac ejection fraction and fractional shortening (p=<0.05). 17β-estradiol treatment significantly attenuated doxorubicin-induced decreases in cardiac ejection fraction and fractional shortening in male rats.

synapsesocial.com/papers/6a7db5c9e5379bb2b27d8927 https://doi.org/10.3892/mmr.2017.6332

View Full Paper

Ask AI

Bookmark

17β-estradiol protects against doxorubicin-induced cardiotoxicity in male Sprague-Dawley rats by regulating NADPH oxidase and apoptosis genes

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

17β-estradiol protects against doxorubicin-induced cardiotoxicity in male Sprague-Dawley rats by regulating NADPH oxidase and apoptosis genes

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Also Consider

Also Consider